+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cephalosporin Drugs Market by Drug Class (Fifth Generation, First Generation, Fourth Generation), Route Of Administration (Intravenous, Oral), Dosage Form, End User, Distribution Channel, Application - Global Forecast 2025-2030- Product Image
Cephalosporin Drugs Market by Drug Class (Fifth Generation, First Generation, Fourth Generation), Route Of Administration (Intravenous, Oral), Dosage Form, End User, Distribution Channel, Application - Global Forecast 2025-2030- Product Image
Sale

Cephalosporin Drugs Market by Drug Class (Fifth Generation, First Generation, Fourth Generation), Route Of Administration (Intravenous, Oral), Dosage Form, End User, Distribution Channel, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011269
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cephalosporin drugs market is evolving as both therapeutic demand and innovation in antimicrobial agents rise. Addressing complexities in resistance, production, and access, the market now demands agile strategies from industry leaders to secure ongoing relevance and performance. Stakeholders need actionable insights to adapt to new clinical drivers and emerging global supply scenarios.

Market Snapshot: Cephalosporin Drugs Market Size and Outlook

The Cephalosporin Drugs Market grew from USD 12.11 billion in 2024 to USD 12.95 billion in 2025. It is projected to continue expanding at a CAGR of 6.68%, reaching USD 17.87 billion by 2030. As foundational agents in antibacterial therapy, cephalosporins are integral to combating a broad range of infections, especially as targeted solutions for evolving pathogenic threats. Ongoing research and regulatory frameworks are shaping how businesses innovate, manufacture, and distribute these critical drugs worldwide.

Scope & Segmentation

  • Drug Classes: Fifth generation, first generation, fourth generation, second generation, third generation (including cefdinir, cefixime, cefotaxime, ceftazidime, ceftriaxone).
  • Route of Administration: Intravenous and oral forms to match both acute inpatient and outpatient care requirements.
  • Dosage Forms: Capsules, injections, powder for reconstitution, and tablets cater to varied patient and hospital needs.
  • End Users: Hospitals, ambulatory surgical centers, clinics, and homecare providers serve distinct patient populations and therapeutic settings.
  • Distribution Channels: Offline (including wholesalers and specialty distributors) and online platforms, supporting both bulk procurement and direct patient delivery.
  • Clinical Applications: Therapeutic focus areas include gonorrhea, respiratory tract infections (bronchitis, pneumonia), sepsis, skin infections, and urinary tract infections, supporting a wide range of medical protocols.
  • Geographies: Americas (with the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (covering key markets such as the UK, Germany, France, Russia, and more), and Asia-Pacific (notably China, India, Japan, Australia, and Southeast Asia).
  • Leading Companies: The competitive landscape features Pfizer Inc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Viatris Inc., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Lupin Limited, Cipla Limited, and Sanofi S.A.

Key Takeaways

  • Technological improvements in diagnostic platforms support targeted deployment of cephalosporins, helping clinicians swiftly match therapy with infection profiles and lower unnecessary broad-spectrum use.
  • Partnerships between pharmaceutical manufacturers, biotechnology specialists, and public health agencies are expediting the development of novel beta-lactamase inhibitors and next-generation cephalosporin analogs.
  • Regulatory evolution, including accelerated pathways, is driving collaboration between market players and government agencies, facilitating faster clinical evaluation and adoption of new therapies.
  • Production agility, achieved by diversifying active pharmaceutical ingredient sourcing and localizing manufacturing, is increasingly vital for uninterrupted supply and rapid market response.
  • Digital platforms and advanced analytics are transforming market intelligence and stakeholder engagement, empowering companies to monitor trends and optimize pricing strategies according to regional nuances.

Tariff Impact: US Tariffs and Global Supply Chains

Revised US tariffs in 2025 have heightened costs in the cephalosporin supply network, pushing manufacturers to pursue more cost-effective sourcing and regional partnerships. These changes are driving greater supply chain resilience as companies explore trade agreement benefits and diversify suppliers. Distribution channels and payer reimbursement models are being recalibrated to offset landed cost pressures and maintain patient access to essential cephalosporins. Strategic engagement with regulators is critical for policies to sustain medicine availability while balancing cost considerations.

Methodology & Data Sources

This report integrates systematic literature reviews, expert interviews, and cross-validated trade and regulatory data. Analytical rigor and triangulation approaches ensure both depth and reliability, providing stakeholders with actionable intelligence grounded in current peer-reviewed and market sources.

The Cephalosporin Drugs Market: Why This Report Matters

  • Delivers clear strategic guidance for optimizing product portfolios in a highly segmented and dynamically regulated market.
  • Helps leaders address supply chain vulnerabilities while identifying growth opportunities driven by technological and regulatory changes.
  • Enables more robust collaboration with key opinion leaders, healthcare providers, and policy makers for greater commercial and clinical impact.

Conclusion

The cephalosporin drugs market requires strategic responsiveness and targeted innovation to meet evolving therapeutic challenges. Informed decisions will depend on supply chain resilience, collaborative research, and continual adaptation to market and regulatory change.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging fifth-generation cephalosporin candidates targeting multidrug resistant Gram-negative infections in hospital settings
5.2. Strategic collaborations between pharmaceutical companies and biotech startups to accelerate novel cephalosporin antibiotic discovery
5.3. Expansion of generic cephalosporin production in Asia Pacific driven by lower manufacturing costs and regulatory support
5.4. Integration of antibiotic stewardship programs to optimize cephalosporin utilization and curb antimicrobial resistance trends
5.5. Pipeline of combination therapies pairing cephalosporins with beta-lactamase inhibitors to overcome extended-spectrum resistant strains
5.6. Government pricing and reimbursement reforms affecting access and affordability of advanced cephalosporin treatments globally
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cephalosporin Drugs Market, by Drug Class
8.1. Introduction
8.2. Fifth Generation
8.3. First Generation
8.4. Fourth Generation
8.5. Second Generation
8.6. Third Generation
8.6.1. Cefdinir
8.6.2. Cefixime
8.6.3. Cefotaxime
8.6.4. Ceftazidime
8.6.5. Ceftriaxone
9. Cephalosporin Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Cephalosporin Drugs Market, by Dosage Form
10.1. Introduction
10.2. Capsule
10.3. Injection
10.4. Powder
10.5. Tablet
11. Cephalosporin Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Homecare
11.5. Hospitals
12. Cephalosporin Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Cephalosporin Drugs Market, by Application
13.1. Introduction
13.2. Gonorrhea
13.3. Respiratory Tract Infections
13.3.1. Bronchitis
13.3.2. Pneumonia
13.4. Sepsis
13.5. Skin Infections
13.6. Urinary Tract Infections
14. Americas Cephalosporin Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cephalosporin Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cephalosporin Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. F. Hoffmann-La Roche Ltd
17.3.3. Teva Pharmaceutical Industries Ltd
17.3.4. Sandoz International GmbH
17.3.5. Viatris Inc.
17.3.6. Dr. Reddy’s Laboratories Ltd
17.3.7. Sun Pharmaceutical Industries Ltd
17.3.8. Lupin Limited
17.3.9. Cipla Limited
17.3.10. Sanofi S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CEPHALOSPORIN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CEPHALOSPORIN DRUGS MARKET: RESEARCHAI
FIGURE 28. CEPHALOSPORIN DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. CEPHALOSPORIN DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. CEPHALOSPORIN DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 134. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 217. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 224. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 225. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 230. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 233. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 236. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 237. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 265. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 268. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 269. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 278. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 279. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 280. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 281. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 284. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 285. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 294. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 295. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 296. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 326. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
TABLE 328. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 330. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 331. S

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Lupin Limited
  • Cipla Limited
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 12.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 17.87 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Cephalosporin Market Report by Generation, Route of Administration, Application, and Region ?2025-2033 - Product Image

Cephalosporin Market Report by Generation, Route of Administration, Application, and Region ?2025-2033

  • Report
  • 144 Pages
  • Global
From
Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class (Carbapenems, Cephalosporins, Monobactam), Route of Administration (Oral Administration, Parenteral Administration), Patient Type, Application, End User - Global Forecast 2025-2030 - Product Image

Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class (Carbapenems, Cephalosporins, Monobactam), Route of Administration (Oral Administration, Parenteral Administration), Patient Type, Application, End User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Cephalosporin Drugs - Global Strategic Business Report - Product Image

Cephalosporin Drugs - Global Strategic Business Report

  • Report
  • 398 Pages
  • Global
From
Cephalosporin Drugs Global Market Report 2025 - Product Image

Cephalosporin Drugs Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Cephalosporin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Cephalosporin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Market

Cephalosporins are a class of antibiotics used to treat a wide range of bacterial infections. They are derived from the fungus Cephalosporium and are closely related to penicillin. Cephalosporins are divided into four generations, each generation having a broader spectrum of activity than the previous one. They are used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. Cephalosporins are also used to treat some sexually transmitted diseases, such as gonorrhea. Cephalosporins are widely used in both human and veterinary medicine. They are available in a variety of formulations, including tablets, capsules, suspensions, and injections. Cephalosporins are generally well tolerated, with few side effects. Some companies in the Cephalosporins market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.